Lynn A. Tetrault is Director at NEOGENOMICS INC (NEO). They have made 8 open-market trades across 1 company since 2015, most recently 2026-06-30.
CIK 0001645512
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $219K since 2015, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NEO | 86,115 | $1.4M |
| RYTM | 11,712 | $1.0M |
| ALMS | 3,553 | $22K |
| Total | $2.5M |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RYTM | SELL · 10b5-1 | 2026-06-22 | 2026-06-24 | $100.32 | $3.7M | +6.7% | -4.9% | -7.4% |
| NEO | SELL | 2026-06-15 | 2026-06-17 | $11.10 | $59K | +37.3% | +37.4% | +77.8% |
| NEO | SELL | 2026-06-09 | 2026-06-11 | $11.29 | $60K | +12.1% | +22.5% | +53.3% |
| NEO | BUY | 2025-05-09 | 2025-05-09 | $8.14 | $114K | -12.6% | -10.7% | -32.0% |
| RYTM | SELL · 10b5-1 | 2024-09-09 | 2024-09-11 | $49.70 | $2.0M | +4.0% | +1.5% | +17.6% |
| RYTM | SELL · 10b5-1 | 2024-08-26 | 2024-08-28 | $50.01 | $215K | +5.0% | +9.8% | +32.5% |
| RYTM | SELL · 10b5-1 | 2024-08-12 | 2024-08-14 | $44.64 | $875K | +6.7% | +5.9% | +36.7% |
| NEO | SELL | 2024-03-04 | 2024-03-06 | $15.97 | $195K | -8.5% | -6.2% | -16.4% |
| NEO | SELL | 2018-11-19 | 2018-11-21 | $16.00 | $208K | +1.2% | -26.7% | +16.0% |
| NEO | SELL | 2018-11-14 | 2018-11-16 | $16.16 | $81K | +3.3% | -22.0% | +8.3% |
| NEO | BUY | 2015-12-21 | 2015-12-23 | $8.21 | $78K | -13.7% | -11.1% | -17.3% |
| NEO | BUY | 2015-12-07 | 2015-12-09 | $7.72 | $27K | -13.7% | -11.5% | -10.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.